Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1‐year follow‐up study

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2005-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2036.2005.02458.xPMID 15854173
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• How effective are the usual treatments for ulcerative colitis?

  2004cited by this paper
• 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study.

  2004cited by this paper
• International Study Group

  2004cited by this paper
• Short‐term adverse effects of 5‐aminosalicylic acid agents in the treatment of ulcerative colitis

  2004cited by this paper
• Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.

  2004cited by this paper
• The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.

  2003cited by this paper
• Maintenance therapy for inflammatory bowel disease.

  2003cited by this paper
• Maintenance of remission in ulcerative colitis

  2002cited by this paper
• Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines

  2002cited by this paper
• REVIEW: Role of 5-Aminosalicylic Acid (5-ASA) in Treatment of Inflammatory Bowel Disease: A Systemic Review

  2002cited by this paper
• Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

  2002cited by this paper
• Azathioprine or methotrexate in the treatment of patients with steroid‐dependent or steroid‐resistant ulcerative colitis: results of an open‐label study on efficacy and tolerability in inducing and maintaining remission

  2002cited by this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2002cited by this paper
• Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects.

  2001cited by this paper
• Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis.

  2001cited by this paper
• Is maintenance therapy always necessary for patients with ulcerative colitis in remission?

  1999cited by this paper
• What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

  1998cited by this paper
• Mesalazine-associated interstitial nephritis: twice in the same patient.

  1997cited by this paper
• Low albumin gradient ascites complicating severe pseudomembranous colitis.

  1997cited by this paper
• Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.

  1997cited by this paper
• Alternatives to Sulfasalazine: A Meta‐analysis of 5‐ASA in the Treatment of Ulcerative Colitis

  1997cited by this paper
• A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis.

  1997cited by this paper
• Adverse events in patients treated with 5‐aminosalicyclic acid: 1993–1994 pharmacovigilance report for Pentasa in France

  1996cited by this paper
• An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis

  1996cited by this paper
• Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study.

  1995cited by this paper
• Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.

  1995cited by this paper
• Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group.

  1995cited by this paper
• Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis

  1995cited by this paper
• Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis

  1995cited by this paper
• Mesalazine induced interstitial nephritis.

  1994cited by this paper
• Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.

  1993cited by this paper
• Sulfasalazine Revisited

  1993cited by this paper
• Comparative efficacy of coated, oral 5‐aminosalicylic acid (Claversal * ) and sulphasalazine for maintaining remission of ulcerative colitis

  1989cited by this paper
• Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.

  1988cited by this paper
• Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth.

  1983cited by this paper
• Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid.

  1982cited by this paper
• In-vitro fertilisation

  1982cited by this paper
• Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

  1980cited by this paper
• CONTROLLED TRIAL OF SULPHASALAZINE IN MAINTENANCE THERAPY FOR ULCERATIVE COLITIS

  1965cited by this paper
• Variation Between Observers in Describing Mucosal Appearances in Proctocolitis*

  1964cited by this paper
• Biopsy Studies in Ulcerative Colitis

  1956cited by this paper
• Noradrenaline in Acute Peripheral Circulatory Failure

  1956cited by this paper
• Cortisone in Ulcerative Colitis

  1954cited by this paper

• Reevaluating aminosalicylates role in maintaining remission in ulcerative colitis: Systematic review and meta-analysis in the era of biologics

  2025cites this paper
• Drug Optimization in Patients with Mild-to-Moderate Ulcerative Colitis: A Global Survey

  2024cites this paper
• Practical management of mild-to-moderate ulcerative colitis: an international expert consensus

  2024cites this paper
• Prevalence and Outcomes of No Treatment Versus 5-ASA in Ulcerative Colitis: A Nationwide Analysis From the epi-IIRN.

  2023cites this paper
• Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction

  2023influential citation
• Treatment of Patients with Mild to Moderate Ulcerative Colitis: A Middle East Expert Consensus

  2023cites this paper
• De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease

  2022cites this paper
• Evidence-based clinical practice guidelines for inflammatory bowel disease 2020

  2021cites this paper
• Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.

  2020cites this paper
• Review article: withdrawal of 5‐aminosalicylates in inflammatory bowel disease

  2020cites this paper
• Effects of Differential Food Patterns on the Pharmacokinetics of Enteric‐Coated Mesalazine Tablets in the Same Cohort of Healthy Chinese Volunteers

  2020cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2020cites this paper
• Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis

  2020cites this paper
• Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease

  2020cites this paper
• AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.

  2019cites this paper
• Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2019cites this paper
• Comparative Efficacy and Tolerability of Pharmacological Agents for Management of Mild to Moderate Ulcerative Colitis: A Network Meta-analysis

  2019cites this paper
• ABOUT TREATMENT OF ULCERATIVE COLITIS

  2018cites this paper
• Study on Follow-Up of Ulcerative Colitis Patients on Sulfasalazine At Our Hospital – Retrospectivecohort Study

  2018cites this paper
• American Gastroenterological Association Institute Guideline on the Management of Mild-Moderate Ulcerative Colitis

  2018cites this paper
• Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.

  2018cites this paper
• Efficacy of Therapeutic Intervention for Patients With an Ulcerative Colitis Mayo Endoscopic Score of 1.

  2018cites this paper
• European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease

  2018cites this paper
• Second Korean guidelines for the management of ulcerative colitis

  2017cites this paper
• [Second Korean Guideline for the Management of Ulcerative Colitis].

  2017cites this paper
• Clinicians’ adherence to international guidelines in the clinical care of adults with inflammatory bowel disease

  2017cites this paper
• Title Efficacy of Long-Term 4 . 0 g / Day Mesalazine ( Pentasa ) for MaintenanceTherapy in Ulcerative Colitis

  2017cites this paper
• Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract.

  2017cites this paper
• Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.

  2017cites this paper
• The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry

  2017cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2016cites this paper
• What is the real-life maintenance mesalazine dose in ulcerative colitis?

  2016cites this paper
• Maintenance therapy options for ulcerative colitis

  2016cites this paper
• Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study

  2016cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2016cites this paper
• Considerations in the management of ulcerative colitis

  2016cites this paper
• [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)].

  2015cites this paper
• Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis.

  2015cites this paper
• A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis.

  2015cites this paper
• Treatment of ulcerative colitis

  2014cites this paper
• Maintenance of Remission in Ulcerative Colitis

  2014cites this paper
• Contrast and Comparison of Mesalamine Derivatives in the Treatment of Ulcerative Colitis

  2014cites this paper
• Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis

  2014cites this paper
• Comparison of QD and TID Oral Mesalazine for Maintenance of Remission in Quiescent Ulcerative Colitis: A Double-blind, Double-dummy, Randomized Multicenter Study

  2013cites this paper
• Ulcerative colitis: prevention of relapse

  2013cites this paper
• Outcome Following Aminosalicylate Therapy in Children Newly Diagnosed As Having Ulcerative Colitis

  2013cites this paper
• Treatment of Ulcerative colitis in the elderly: A systematic Review

  2013cites this paper
• Expert Review of Gastroenterology & Hepatology

  2013cites this paper
• Guidelines for the management of ulcerative colitis. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology

  2012cites this paper
• Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management

  2012cites this paper
• [Guidelines for the management of ulcerative colitis].

  2012cites this paper
• Improving Delivery of Aminosalicylates in Ulcerative Colitis

  2012cites this paper
• Management of Pediatric Ulcerative Colitis: Joint ECCO and ESPGHAN Evidence-based Consensus Guidelines

  2012cites this paper
• Randomized controlled clinical trials in mild-moderate ulcerative colitis.

  2012cites this paper
• Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.

  2012cites this paper
• Conventional Medical Management of Ulcerative Colitis: Sulfasalazine and 5-Aminosalicylates

  2012cites this paper
• 궤양성 대장염 치료 가이드라인

  2012cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2012cites this paper
• Randomised clinical trial: a comparative dose‐finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis

  2011cites this paper
• One-year Investigator-blind Randomized Multicenter Trial Comparing Asacol 2.4 g Once Daily with 800 mg Three Times Daily for Maintenance of Remission in Ulcerative Colitis

  2011cites this paper
• An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease

  2011cites this paper
• Review article: defining remission in ulcerative colitis

  2011cites this paper
• Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis

  2011cites this paper
• Conventional medical management of inflammatory bowel disease.

  2011cites this paper
• Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine

  2010cites this paper
• Advances In Inflammatory Bowel Diseases

  2009cites this paper
• Clinical trial: ulcerative colitis maintenance treatment with 5‐ASA: a 1‐year, randomized multicentre study comparing MMX® with Asacol®

  2009cites this paper
• Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.

  2009cites this paper
• MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis.

  2009cites this paper
• Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.

  2008cites this paper
• An unexpected cause of chronic diarrhoea

  2008cites this paper
• Duration of remission and long‐term prognosis according to the extent of disease in patients with ulcerative colitis on continuous mesalamine treatment

  2008cites this paper
• Manipulation of intestinal microbial flora for therapeutic benefit in inflammatory bowel diseases: review of clinical trials of probiotics, pre-biotics and synbiotics.

  2008cites this paper
• European evidence-based Consensus on the management of ulcerative colitis: Current management.

  2008cites this paper
• Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

  2008cites this paper
• Drug Insight: aminosalicylates for the treatment of IBD

  2007cites this paper
• Is Once‐Daily Mesalazine Equivalent to the Currently Used Twice‐Daily Regimen? A Study Performed in 30 Healthy Volunteers

  2007cites this paper
• The role of mesalamine in the treatment of ulcerative colitis

  2007cites this paper
• Systematic review: the use of mesalazine in inflammatory bowel disease

  2006cites this paper
• Optimizing management of distal ulcerative colitis

  2006cites this paper
• Review article: maintenance therapy in patients with ulcerative colitis

  2006cites this paper
• What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis?

  2005cites this paper